Reslizumab: all 21 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 AntagonistsCompletedNCT04183192Phase 1Results posted
• A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic AsthmaTerminatedNCT03052725Phase 3Results posted
• An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway InflammationTerminatedNCT02937168Phase 4Results posted
• An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood EosinophilsCompletedNCT02501629Phase 3Results posted
• Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood EosinophilsCompletedNCT02452190Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe AsthmaCompletedNCT01508936Phase 3Results posted
• Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic AsthmaTerminatedNCT01290887Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic AsthmaCompletedNCT01287039Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic AsthmaCompletedNCT01285323Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic AsthmaCompletedNCT01270464Phase 3Results posted
• Reslizumab to Prevent Post-treatment Eosinophilia in LoiasisCompletedNCT01111305Phase 2Results posted
• Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic EsophagitisCompletedNCT00635089Phase 3Results posted
• Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled AsthmaCompletedNCT00587288Phase 2Results posted
• Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 YearsCompletedNCT00538434Phase 2/3Results posted
• Efficacy of Reslizumab Dose Escalation in Patients With Severe AsthmaCompletedNCT04710134Phase 4
• Reslizumab in Patients With Severe Asthma Who Failed to Respond to OmalizumabCompletedNCT03074942Phase 2
• Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) StudyStatus unknownNCT02947945Phase 2
• Effect of Reslizumab in Chronic RhinosinusitisStatus unknownNCT02799446Phase 3
• Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic AsthmaCompletedNCT02559791Phase 2/3
• Absolute Bioavailability of Reslizumab in Healthy SubjectsCompletedNCT01990443Phase 1
• Anti-Interleukin-5 Antibody to Treat Hypereosinophilic SyndromeCompletedNCT00017862Phase 2

← Reslizumab overview